Daiichi Sankyo Launches Anti-Clotting Drug In France, Italy
This article was originally published in PharmAsia News
Executive SummaryDaiichi Sankyo has launched its newly approved Effient (prasugrel) in France and Italy, expanding its reach to 22 nations to prevent blood clotting
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.